⌕
Allogene Therapeutics · ALLO · Nasdaq
Tenet 65 · Solid
Compare
$0.70−6.48%At closeTenet 65 · Solid
$0.70−0.05 (−6.48%)
At close: Nov 18, 2026, 4:00 PM ET· Nasdaq · USD

Allogene Therapeutics (ALLO) Stock

Allogene Therapeutics (ALLO) closed at $0.70 on Nov 18, 2026; its Tenet Score is 65 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$0.70
Nov 18, 2026
Market cap
$257.8M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
0.74 – 4.46
low → high · as of close, Nov 17, 2026
Tenet Score
65/100
Solid · 340 Healthcare peers

Industry: Health Services

Allogene Therapeutics Inc scores 65/100. Solid. Strongest on value and financial health, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 65 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
65/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
99
Quality
13
Health
82
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueA+QualityFHealthBGrowth—MomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.7×
Sep 30, 2026 balance sheet
P/S
55.6×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 17, 2026
ROE
−49%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
7.79
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric…

Composite computed Nov 17, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 51 US ETFs · top wrappers by weightSee all ETFs holding ALLO →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 17, 2026.

What sector and industry is Allogene Therapeutics in?

Allogene Therapeutics is in the Healthcare sector and the Health Services industry.

What is Allogene Therapeutics' Tenet Score?

Allogene Therapeutics' Tenet Score is 65 out of 100, ranked against 340 Healthcare peers as of Nov 17, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.